Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details related to executive compensation.
- Share Price: 1450.50 pence per Ordinary Share and $46.91 per ADS.
- Transaction Date: October 10, 2012 (Notification date).
- Dividend Re-investment Date: October 4, 2012.
Material Changes
The filing reports increases in notional interests in Ordinary Shares and American Depositary Shares (ADSs) for various executives following the re-investment of dividends. No material changes to the company's financial position or operations are disclosed in this specific report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of specific share transactions.
Important Facts for Investors
- Executive Acquisitions: Multiple directors and managers, including Sir Andrew Witty, acquired Ordinary Shares or ADSs through personal contributions and company matching under the Deferred Annual Bonus Plan.
- Transaction Volume: Acquisitions ranged from 56 ADSs (Mr W C Louv) to 1,306 Ordinary Shares (Sir Andrew Witty) per element (personal and matching).
- Valuation Basis: All transactions were executed at a price of 1450.50 pence per Ordinary Share.
- Payout Terms: Notional dividends accrued will be paid out based on the percentage of deferred annual bonus holdings vesting after a three-year measurement period.